Skip to main content
  • Saved

Commented on 's Post

Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients - PubMed

Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients - PubMed

Source :

https://pubmed.ncbi.nlm.nih.gov/33856638/

The global, randomized, open-label KEYNOTE-183 phase 3 study was closed early after an interim analysis showed unfavorable risk-benefit when pembrolizumab was added to pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM). This subgroup analysis reported outcom ...

  • 1 week 3 days
    Small numbers in this retrospective analysis. At most hypothesis generating but seems unlikely that this will see additional work